

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 20 February 2021

Situation Report No. 235 - Kingdom of Bahrain
21th of February, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	110,384,747	2,446,008	6,155,544	141,597
New	1,732,497 in 5 days	47,119 in 5 days	131,692 in 5 days	1,817 in 5 days


Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	117,234	109,085	420	7,729	68	2,980,752
New	3,644 in 5 days	3,301 in 5 days	14 in 5 days	-	-	67,212 in 5 days

HIGHLIGHTS

- The mortality were: 9 Bahraini citizens [8 male (49, 55, 67, 75, 79, 83, 87 and 92 years old)] and 1 female (77 years old), and 5 expatriates [3 male (43, 49 and 51 years old) and 2 female (62 and 73 years old)].
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 20 February 2021 is 271,749.
- Additional precautionary measures for travelers arriving into the Kingdom of Bahrain are instituted effective Monday, 22 February 2021
- Bahrain began administering the Sputnik V vaccine within its National Vaccination Campaign
- Implementing recommendations of National Medical Taskforce for Combating COVID-19, the following decisions were made, effective from 21 February 2021 to 14 March 2021:
 - All government entities and institutions to allow a maximum of 70% of employees to work from home
 - Temporary suspension of in person learning across all nurseries, public and private schools as well as higher education institutes and universities
 - Temporary suspension of in person activities at government rehabilitation centres affiliated with the Ministry of Labour and Social Development
 - Temporary suspension of in person activities at nurseries and private training institutes licensed by the Ministry of Labour and Social Development
 - Temporary closure of in-door gyms, sports halls and swimming pools, including all indoor exercise classes
 - Outdoor exercise as part of gym and sports halls, including exercise classes, may continue with a maximum of 30 participants
 - Temporarily limit dining services to outdoors
 - Any social event or gathering in a private residence or other private space with more than 30 participants is strictly prohibited
- Registration to receive COVID-19 vaccination is via either: The BeAware Application or by calling 444.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines; see link below.
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020; see link below.
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021; see link below.
- WHO: Contact tracing in the context of COVID-19; see link below.
- WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19; see link below.
- WHO: COVID-19-Occupational health and safety for health workers; see link below.
- WHO: Weekly operational update on COVID-19 - 13 February 2021; see link below.
- WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out; see link below.


Number of New Cases




IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b6d49a16_4
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/25v9d50>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: [https://www.who.int/publications/item/emergency-global-supply-chain-system-\(covid-19\)-catalogue](https://www.who.int/publications/item/emergency-global-supply-chain-system-(covid-19)-catalogue)
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: bit.ly/2l0j0Vf
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2J0wWlQ>
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/item/9789240017467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/10665337553>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: <https://www.who.int/publications/item/1120152020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based_international_travel_Assessment_tool-2020.1
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health: <https://www.who.int/publications/item/9789240018440>
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: https://www.who.int/publications/item/WHO-2019-nCoV-vaccine-SAGE_recommendation-BNT162b2-2021.1
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum: <https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum>
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: https://www.who.int/publications/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: [https://www.who.int/publications/item/background-document-on-mrna-vaccine-bnt162b2-\(pfizer-biotech\)-against-covid-19](https://www.who.int/publications/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biotech)-against-covid-19)
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum: <https://www.who.int/news/item/15-01-2021-scientists-tackle-vaccine-safety-efcacy-and-access-at-global-r-d-forum>
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines: <https://www.who.int/news/item/15-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines>
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020: <https://www.who.int/publications/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021: <https://www.who.int/publications/item/covid-19-virtual-press-conference-transcript-1-february-2021>
- WHO: Contact tracing in the context of COVID-19: <https://www.who.int/publications/item/contact-tracing-in-the-context-of-covid-19>
- WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19: [https://www.who.int/publications/item/background-document-on-the-mrna-1273-vaccine-\(moderna\)-against-covid-19](https://www.who.int/publications/item/background-document-on-the-mrna-1273-vaccine-(moderna)-against-covid-19)
- WHO: COVID-19-Occupational health and safety for health workers: https://www.who.int/publications/item/WHO-2019-nCoV-HCW_advice-2021.1
- WHO: Weekly operational update on COVID-19 - 13 February 2021: <https://www.who.int/publications/item/weekly-operational-update-on-covid-19-13-february-2021>
- WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out: <https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out>

Total Number of Cases



Number of New Deaths



IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAIi5@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh